Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 926 results for "hepatitis"

ILBS designated as WHO collaborating centre on viral hepatitis

government-run institute is the second collaborating centre in the world on viral Hepatitis and the first for liver diseases. The only other WHOCC in Hepatitis is the Centre for Disease Control and Prevention (CDC) in Atlanta, USA. WHOCC are institutions such ... Business Standard, 44 minutes ago

624 images for hepatitis

Med India, 1 day ago
Med India, 11 hours ago
NPR, 4 days ago
NPR, 4 days ago
China Post, 3 days ago
MedicineNet.com, 1 day ago
MedIndia, 5 days ago
Bidness Etc, 4 days ago
KUNM, 4 days ago
MedIndia, 1 week ago
Press TV

AFP - Spain-healthcare-drugs-virus-demonstration

Spain-healthcare-drugs-virus-demonstration Contributed by NAMPA / AFP. Spain hepatitis patients say cutbacks block vital drugs =(PICTURE)= MADRID, Dec 27, 2014 (AFP) - Several hundred hepatitis C sufferers and their supporters protested in ...
 Namibia Press Agency1 day ago Spain hepatitis patients slam spending cuts  The Gulf Today19 hours ago Spain hepatitis patients stage protest  Press TV21 hours ago Spain hepatitis patients say cutbacks block vital drugs  News.net1 day ago
[x]  
UnitedHealthcare

Number of the day: $83,319

That's the amount it will cost for a 12-week regimen of a new hepatitis C drug approved for marketing by the U.S. Food and Drug Administration (FDA) last week. The treatment, which goes by the name Viekira Pak, is made up of four different ...
 UnitedHealthcare1 day ago US FDA approves Abbvie's Viekira Pak to treat chronic genotype 1 hepatitis C  PharmaBiz5 days ago FDA Approves Combo Hepatitis C Treatment  WebMD5 days ago Abbvie Versus Gilead In Hepatitis C, With Comments On Biotech  Seeking Alpha5 days ago
[x]  

4 Potential Blockbuster Drugs The FDA Just Approved

While the approval of AbbVie 's (NYSE: ABBV ) hepatitis C regimen Viekira Pak hogged most of the headlines , over the past week the FDA has approved a whole passel of medicines that could be blockbusters for their makers. Here's a short list of ...
 Investor's Business Daily1 day ago
Miami Herald

Minot hepatitis C outbreak now up to 51 cases

Dave Barry (Mondays) Don't miss Dave's newest column or weblog post. Health & Fitness (Tuesday) Eat and exercise the South Florida way. Weekend Concierge When mid-week rolls around, it's time to start thinking about play. Get the latest ...
 Miami Herald4 days ago Enanta Is The Big Winner In The Hepatitis C War Between Abbvie And Gilead  Seeking Alpha5 days ago AbbVie supplants Gilead as Hepatitis C fighter  Catholic Online4 days ago The nation's largest pharmacy benefits manager is throwing its weight into the fight over high-cost hepatitis C drugs with a coverage restriction that might ultimately lower prices and improve patient ...US stocks push to record highs, continuing a rally  Yahoo! Finance5 days ago
[x]  
Motley Fool

The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)

For shareholders of Gilead Sciences (NASDAQ: GILD Gilead's giant leap forward Sovaldi and Harvoni both represent major breakthroughs in HCV patient quality of care in that neither Sovaldi (geared toward genotype 2 and 3 HCV) nor Harvoni (targeted ...
 Motley Fool4 days ago Fight Over $1,100 Hepatitis C Pills Waits for Next Move by CVS  Washington Post5 days ago AbbVie lowers price of hepatitis C drug to win deal with Express Scripts  Chicago Tribune5 days ago Hepatitis C pill fight: What will CVS do?  LifeHealthPro4 days ago
[x]  

Hepatitis Breaks Social Barrier, Penetrates Primitive Tribal Groups

BHUBANESWAR: Primitive tribal groups (PTGs) of Odisha like Mankadia, Juanga, Khadia, Lodha and Saora are carrying an alarmingly high Hepatitis B (HBV) load to the tune of over 15 per cent. The prevalence, surpassing the national rate between two ...
 New Indian Express2 days ago Razors Spreading Hepatitis B?  New Indian Express2 days ago
MedIndia

Goodbye Time for Interferon In Treating Hepatitis C ...

The US Food and Drug Administration (FDA) has recently granted approval for interferon-free treatment for those affected with hepatitis C genotype 1. The treatment offers a 12-week IFN-free, all-oral course. The Treatment: The combination ...
 MedIndia2 days ago Goodbye Time To Interferon In Treating Hepatitis C Genotype 1  Med India1 day ago goodbye-time-for-interferon-in-treating-hepatitis-c-genotype-1-145260-1.htmGoodbye Time To Interferon In Treating Hepatitis C Genotype 1  MedIndia2 days ago
US News & World Report

Hepatitis C Infection Isn't Related to HIV Brain Woes: Study

By Robert Preidt, HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Hepatitis C infection does not contribute to mental decline in people with HIV, according to a new study. Treatment advances have made it possible for people ...
 US News & World Report3 days ago India: Police fear prevents HIV-infected Drug users to access Healthcare  Med India1 month ago
[x]  
Bidness Etc

Gilead Sciences (GILD) May Have To Cut Price Of Hepatitis C Drug To Battle Competition

Gilead Sciences, Inc. ( NASDAQ:GILD ) may eventually be forced to lower prices of its hepatitis C drugs after Express Scripts Holding Company ( NASDAQ:ESRX ) announced earlier this week that it will drop Gilead's hepatitis C treatment from its list ...
 Bidness Etc4 days ago Should Gilead Sciences Inc Negotiate Its Way Back On Express Scripts (ESRX) Formulary?  Bidness Etc2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less